{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:45:03Z","timestamp":1790635503478,"version":"4.1.0"},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"abstract":"<jats:p>Elevated plasma Lp(a) levels, which occur in as many as 1.5 billion people worldwide, are an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Unlike low-density lipoprotein cholesterol, Lp(a) levels are approximately 90% genetically determined. Currently, no approved pharmacological therapies specifically target lowering Lp(a) concentrations. Several drugs, mainly RNA-based therapies, that specifically and potently lower Lp(a), are under investigation. Three of these new therapeutic agents are advancing through clinical development to evaluate whether reducing Lp(a) levels can decrease cardiovascular risk. The outcomes of these trials could potentially transform cardiovascular disease prevention strategies; however, once approved, the drugs will likely be used for secondary prevention and ongoing strategies for managing elevated Lp(a) in primary prevention will be important. Lipoprotein(a) research is a rapidly evolving field, but unanswered questions remain concerning the physiological function of Lp(a) and its true pathogenic mechanisms.<\/jats:p>","DOI":"10.5114\/aoms\/202213","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:12:01Z","timestamp":1740240721000},"source":"Crossref","is-referenced-by-count":17,"title":["2024: The Year in Cardiovascular Disease - The Year of Lipoprotein(a) \u2013 Research Advances and New Findings."],"prefix":"10.5114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8988-4150","authenticated-orcid":false,"given":"Bo\u017cena","family":"Sosnowska","sequence":"first","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-5460","authenticated-orcid":false,"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center, Sterling, IL, USA, United States"},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA., United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-0876","authenticated-orcid":false,"given":"Alexander C","family":"Razavi","sequence":"additional","affiliation":[{"name":"Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5839-7280","authenticated-orcid":false,"given":"Alan T","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-3168","authenticated-orcid":false,"given":"Roger S","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA., United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland, Poland"},{"name":"Faculty of Medicine, the John Paul II Catholic University of Lublin (KUL), Lublin, Poland, Poland, Poland"},{"name":"Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother\u2019s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland., Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,2,22]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-202213-122760","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-202213-122760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:12:01Z","timestamp":1740240721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/2024-The-Year-in-Cardiovascular-Disease-The-Year-of-Lipoprotein-a-Research-Advances,202213,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":0,"alternative-id":["202213"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/202213","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]}}}